Skip to main content

Peer Review reports

From: Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan

Original Submission
19 Apr 2021 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
27 Apr 2021 Reviewed Reviewer Report
2 May 2021 Reviewed Reviewer Report
8 May 2021 Author responded Author comments - Te Sheng Chang
Resubmission - Version 3
8 May 2021 Submitted Manuscript version 3
11 May 2021 Author responded Author comments - Te Sheng Chang
Resubmission - Version 4
11 May 2021 Submitted Manuscript version 4
11 May 2021 Author responded Author comments - Te Sheng Chang
Resubmission - Version 5
11 May 2021 Submitted Manuscript version 5
12 May 2021 Reviewed Reviewer Report
18 May 2021 Author responded Author comments - Te Sheng Chang
Resubmission - Version 6
18 May 2021 Submitted Manuscript version 6
Publishing
31 May 2021 Editorially accepted
12 Jun 2021 Article published 10.1186/s12876-021-01837-y

You can find further information about peer review here.

Back to article page